This is a binary catalyst event — the stock will move on any subsequent partnership announcement or lack thereof. Monitor for material definitive agreements (Item 1.01 8-K) or equity financing (Item 3.02) in the coming weeks. The company's $6M market cap and pre-revenue status mean any deal could be transformative, but failure to secure a partner would likely be viewed negatively given the explicit monetization process.
Price Chart
Executive Summary
Cadrenal Therapeutics announced a strategic realignment of its pipeline into a Cardiac Acute Critical Care Franchise and initiated a formal partnering process to out-license, monetize, or co-develop its late-stage assets (CAD-1005, frunexian, tecarfarin). The announcement follows positive Phase 2 CAD-1005 data ( >25% absolute reduction in thrombotic events) presented at ISTH 2026. While the partnering process signals potential non-dilutive funding and validation, the company has no current revenue, a $6M market cap, and the filing contains no binding agreements or financial terms — making this a speculative catalyst with binary execution risk.
Key Facts
- Cadrenal initiated a structured process to secure strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets (CAD-1005, frunexian, tecarfarin).
- Phase 2 CAD-1005 data presented at ISTH 2026 demonstrated a >25% absolute reduction in thrombotic events in patients with heparin-induced thrombocytopenia.
- The pipeline is reorganized into three pillars: Pre-Operative Safety (frunexian, Phase 2-ready), Orphan Regulatory Acceleration (tecarfarin, Phase 3-ready), and Post-Operative Shield (CAD-1005, Phase 3-ready).
- No binding agreements, financial terms, or revenue figures were disclosed in the filing.
- The company has a $6M market cap and no approved products or current revenue.
Financial Impact
No financial terms disclosed; potential for non-dilutive partnership income but entirely speculative at this stage.
Risk Factors
- No binding agreements or financial terms have been reached — the partnering process may fail to yield a deal.
- The company has a $6M market cap and no revenue; cash runway and dilution risk remain unaddressed in this filing.
- Forward-looking statements about partnership-driven commercialization are aspirational and not guaranteed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-079824 |
| Document: ea029866901ex99-1.htm | 0001213900-26-079824 |
| Document: 0001213900-26-079824-index-headers.html | 0001213900-26-079824 |
| Document: 0001213900-26-079824-index.html | 0001213900-26-079824 |
| Document: 0001213900-26-079824.txt | 0001213900-26-079824 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | 8-K | $0.9723 | awaiting T+60 | — | $0.9098 (−6.43%) |
Aug 31, 2026 8w ago | 8-K | $1.75 | awaiting T+60 | — | $0.9098 (−48.01%) |
Jul 21, 2026 14w ago | 8-K | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9098 (−58.07%) |
Jul 21, 2026 14w ago | EFFECT | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9098 (−58.07%) |
Jul 1, 2026 16w ago | Press Release | $3.60 $1.12 | ▲ +68.89% | ▲ +71.94% | $0.9098 (+74.73%) |
Jun 29, 2026 17w ago | 8-K | $3.34 $1.32 | ▼ −60.48% | ▼ −64.04% | $0.9098 (−72.76%) |
Jun 18, 2026 18w ago | 8-K | $3.50 $1.06 | ▼ −69.71% | ▼ −71.61% | $0.9098 (−74.01%) |
Jun 15, 2026 19w ago | 144 | $3.04 $1.18 | ▲ +61.18% | ▲ +62.18% | $0.9098 (+70.07%) |
May 7, 2026 24w ago | Press Release | $6.02 $1.96 | ▼ −67.44% | ▼ −71.27% | $0.9098 (−84.89%) |
Apr 30, 2026 25w ago | 8-K | $6.67 $2.06 | ▼ −69.12% | ▼ −72.22% | $0.9098 (−86.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers